CN114404646B - CM-β-CD负载鞣酸聚丙烯酰胺型双网络抗菌水凝胶 - Google Patents
CM-β-CD负载鞣酸聚丙烯酰胺型双网络抗菌水凝胶 Download PDFInfo
- Publication number
- CN114404646B CN114404646B CN202111630532.XA CN202111630532A CN114404646B CN 114404646 B CN114404646 B CN 114404646B CN 202111630532 A CN202111630532 A CN 202111630532A CN 114404646 B CN114404646 B CN 114404646B
- Authority
- CN
- China
- Prior art keywords
- beta
- cyclodextrin
- tannic acid
- supported
- network
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000017 hydrogel Substances 0.000 title claims abstract description 64
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 36
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 title claims abstract description 35
- 239000001263 FEMA 3042 Substances 0.000 title claims abstract description 35
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 title claims abstract description 35
- 229920002258 tannic acid Polymers 0.000 title claims abstract description 35
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 title claims abstract description 35
- 229940033123 tannic acid Drugs 0.000 title claims abstract description 35
- 235000015523 tannic acid Nutrition 0.000 title claims abstract description 35
- 229920002401 polyacrylamide Polymers 0.000 title claims abstract description 12
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims abstract description 46
- 229920001661 Chitosan Polymers 0.000 claims abstract description 26
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims abstract description 13
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 claims abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 238000000227 grinding Methods 0.000 claims description 20
- 238000002360 preparation method Methods 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 19
- 229920001864 tannin Polymers 0.000 claims description 18
- 235000018553 tannin Nutrition 0.000 claims description 18
- 239000001648 tannin Substances 0.000 claims description 18
- 229920000858 Cyclodextrin Polymers 0.000 claims description 17
- 239000001116 FEMA 4028 Substances 0.000 claims description 16
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 16
- 229960004853 betadex Drugs 0.000 claims description 16
- 238000003756 stirring Methods 0.000 claims description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- 239000006185 dispersion Substances 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 12
- 239000008367 deionised water Substances 0.000 claims description 11
- 229910021641 deionized water Inorganic materials 0.000 claims description 11
- 230000000845 anti-microbial effect Effects 0.000 claims description 10
- 239000003431 cross linking reagent Substances 0.000 claims description 8
- 239000003999 initiator Substances 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 7
- 238000006266 etherification reaction Methods 0.000 claims description 7
- 239000003513 alkali Substances 0.000 claims description 6
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 claims description 6
- 229940106681 chloroacetic acid Drugs 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 238000009210 therapy by ultrasound Methods 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- -1 N,N’-Methylene Chemical group 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims description 2
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims description 2
- 230000009977 dual effect Effects 0.000 claims 3
- 239000002131 composite material Substances 0.000 abstract description 5
- 239000000463 material Substances 0.000 abstract description 4
- 230000003647 oxidation Effects 0.000 abstract description 4
- 238000007254 oxidation reaction Methods 0.000 abstract description 4
- 239000000243 solution Substances 0.000 description 10
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 description 8
- 238000006116 polymerization reaction Methods 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 206010018910 Haemolysis Diseases 0.000 description 5
- 230000008588 hemolysis Effects 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 5
- 239000002121 nanofiber Substances 0.000 description 5
- CUJVBAPGYBSBHJ-YWBSARSQSA-N 2-[[(1R,3R,5R,6S,8R,10R,11S,13R,15R,16S,18R,20R,21R,23R,25R,26R,28R,30R,31R,33R,35R,36R,37R,38R,39R,40R,41R,42R,43R,44R,45R,46R,47R,48R,49R)-36,38,40,42-tetrakis(carboxymethoxy)-10,15-bis(carboxymethoxymethyl)-37,39,41,43,44,45,46,47,48,49-decahydroxy-20,25,30,35-tetrakis(hydroxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontan-5-yl]methoxy]acetic acid Chemical compound OC[C@H]1O[C@@H]2O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCC(O)=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCC(O)=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCC(O)=O)O[C@@H]3[C@@H](CO)O[C@H](O[C@@H]4[C@@H](CO)O[C@H](O[C@@H]5[C@@H](CO)O[C@H](O[C@H]1[C@H](OCC(O)=O)[C@H]2O)[C@H](O)[C@H]5OCC(O)=O)[C@H](O)[C@H]4OCC(O)=O)[C@H](O)[C@H]3OCC(O)=O CUJVBAPGYBSBHJ-YWBSARSQSA-N 0.000 description 4
- 229910001870 ammonium persulfate Inorganic materials 0.000 description 4
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000003113 alkalizing effect Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- VGPXMTPKYDNMQA-UHFFFAOYSA-N furan-2,5-dione;prop-2-enamide Chemical compound NC(=O)C=C.O=C1OC(=O)C=C1 VGPXMTPKYDNMQA-UHFFFAOYSA-N 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 239000004570 mortar (masonry) Substances 0.000 description 3
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallyl group Chemical group C1(=C(C(=CC=C1)O)O)O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical class [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 206010051373 Wound haemorrhage Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 229920000867 polyelectrolyte Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229940079877 pyrogallol Drugs 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000010526 radical polymerization reaction Methods 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F222/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a carboxyl radical and containing at least one other carboxyl radical in the molecule; Salts, anhydrides, esters, amides, imides, or nitriles thereof
- C08F222/04—Anhydrides, e.g. cyclic anhydrides
- C08F222/06—Maleic anhydride
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0014—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0085—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0095—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L27/48—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with macromolecular fillers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/60—Materials for use in artificial skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/21—Acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/236—Glycosaminoglycans, e.g. heparin, hyaluronic acid, chondroitin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/10—Materials or treatment for tissue regeneration for reconstruction of tendons or ligaments
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Medicinal Chemistry (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Composite Materials (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Abstract
本发明公开了一种CM‑β‑CD负载鞣酸聚丙烯酰胺型双网络抗菌水凝胶,涉及抗菌水凝胶技术领域,按重量组分计,包括80‑100份丙烯酰胺、40‑50份马来酸酐、16‑20份壳聚糖、4‑8份羧甲基化β‑环糊精和2‑4份单宁酸;本发明制备出具有结构适应性强、孔隙率高、粘附性能优异、抗氧化能力强和抗菌活性强等优点的复合双网络型水凝胶,有望作为支架材料应用于更广泛的生物医学领域。
Description
技术领域:
本发明涉及抗菌水凝胶技术领域,具体涉及一种CM-β-CD负载鞣酸聚丙烯酰胺型双网络抗菌水凝胶及其制备方法。
背景技术:
遭受机械创伤、烧伤、手术、战斗创伤等造成的皮肤创伤通常伴随着伤口出血和细菌感染,有时还会导致死亡。因此,使用伤口敷料来有效控制出血、细菌感染和保护内脏器官是创伤创面治疗的迫切需要。迄今为止,伤口敷料已开发成不同形式,如海绵、水凝胶、薄膜和纳米纤维垫。在这些敷料中,水凝胶由于其高比表面积、互连网络、不同孔径的高孔隙率以及模拟天然细胞外基质的结构而得到了更多的研究。水凝胶通常不具有较强的粘附能力,甚至同一种水凝胶的胶块之间也不会产生粘附,水凝胶的强附着力必须依赖于水凝胶内部的聚合物网络,因此制备具有优异粘附性的水凝胶仍然是一个具有挑战性的问题。
壳聚糖是自然界中仅次于纤维素的第二丰富的生物高聚物,是一种天然、无毒、生物相容、可生物降解的多糖。此外,由于其独特的止血和抗菌活性,壳聚糖广泛用于伤口愈合,但它本身的细胞亲和力较差,机械强度不足,这限制了它在生物医学应用中的应用。
环糊精是由α-(1-4)糖苷键连接的6、7或8个D-葡萄糖单元组成的环状低聚糖。它们具有疏水性的内部空间和亲水性的外部表面,可与多种分子产生主客体相互作用,但β-环糊精溶解度低,且影响其与客体形成包容物的水溶性,限制其应用范围;因此需要将β-环糊精改性处理。单宁酸在各种植物中含量丰富,其分子结构中含有高含量的邻苯二酚和邻苯三酚片段,因此具有高抗氧化性、高粘附性、抗菌性和抗炎性。
现有技术中,例如专利CN 109762182B公开了一种抗菌水凝胶的制备方法,该水凝胶以聚乙烯醇和单宁酸为原料,采用冻融法制备,步骤繁琐,需多次冷冻-解冻,耗时长,制备的水凝胶形成的抑菌圈较小,抗菌性能较差;专利CN 113274543A公开了一种黏附抗菌温度耐受功能水凝胶的制备方法,但是其引入了常见抗菌剂聚赖氨酸、季铵盐壳聚糖、聚六亚甲基胍盐酸盐等高分子抑菌剂,粘附性能不强,制得的抗菌水凝胶的生物相容性较差,对皮肤具有一定的刺激性。
因此,如何制备出抗菌性能优异、粘附性强且力学性能较好的抗菌型水凝胶,是本领域技术人员急需解决的技术问题。本发明在壳聚糖水溶液中通过丙烯酰胺和马来酸酐单体的原位聚合,在壳聚糖和P(MAH-r-AM)之间进行离子配位,提出了一类新型的超分子纳米纤维结构杂化水凝胶。
发明内容:
本发明所要解决的技术问题在于提供一种CM-β-CD负载鞣酸聚丙烯酰胺型双网络抗菌水凝胶及其制备方法,以解决现有技术中制备的抗菌型水凝胶黏附性能差、抗菌性能不强、生物相容性不高等问题。
本发明所要解决的技术问题采用以下的技术方案来实现:
本发明的一个目的是提供一种CM-β-CD负载鞣酸聚丙烯酰胺型双网络抗菌水凝胶,按重量组分计,包括80-100份丙烯酰胺、40-50份马来酸酐、16-20份壳聚糖、4-8份羧甲基化β-环糊精和2-4份单宁酸。
本发明的另一个目的是提供一种上述水凝胶的制备方法,包括如下步骤:
(1)羧甲基化β-环糊精的干法制备:取β-环糊精研细,加碱研磨,再滴入无水乙醇和水研磨,碱化后加入氯乙酸,研磨一段时间后放入烘箱中,取出后继续研磨,如此反复进行醚化反应,最后用乙醇洗涤,烘干;
(2)羧甲基化β-环糊精/单宁酸分散液的制备:将步骤(1)制备的羧甲基化β-环糊精粉末加入到去离子水中,搅拌后超声处理,并加入单宁酸,制得羧甲基化β-环糊精/单宁酸分散液;
(3)水凝胶的制备:将马来酸酐溶解于去离子水中,再加入壳聚糖混合,得到壳聚糖-马来酸酐溶液;然后将丙烯酰胺、步骤(2)制备的羧甲基化β-环糊精/单宁酸分散液加入到壳聚糖-马来酸酐溶液中,反应一段时间后,降温加入引发剂、交联剂进行反应,得到CM-β-CD负载鞣酸聚丙烯酰胺型双网络抗菌水凝胶。
所述步骤(1)中碱为NaOH。
所述步骤(1)中碱化时间为0.5-1.5h。
所述步骤(1)中碱与β-环糊精的重量比为(0.2-0.25):1。
所述步骤(1)中醚化反应时的烘箱温度为40℃-50℃。
所述步骤(1)中β-环糊精与氯乙酸的摩尔用量比为(4-6):1。
所述步骤(3)中反应温度为50-60℃,反应时间为2-3h,降低温度至30-40℃。
所述步骤(3)中引发剂为过硫酸钾。
所述步骤(3)中交联剂为N,N’-亚甲基双丙烯酰胺。
本发明的有益效果是:
1、本发明利用壳聚糖水溶液中马来酸酐和丙烯酰胺单体的原位聚合,在壳聚糖和聚合(丙烯酰胺-马来酸酐)之间进行离子配位,制备了一类新型的超分子纳米纤维结构杂化水凝胶;壳聚糖在高浓度或高温度下倾向于通过平行排列聚集成纳米纤维,是形成杂化水凝胶刚性部分的理想组分。而软P(MAH-r-AM)链可以为杂化水凝胶提供弹性和亲水性,进一步增强水凝胶的机械性能;再通过羧甲基化改性β-环糊精,加入单宁酸(鞣酸),增强其与客体单宁酸形成包容物的水溶性,进一步提高了对细菌的抗菌活性以及体外抗氧化能力;制备出具有结构适应性强、孔隙率高、粘附性能优异、抗氧化能力强和抗菌活性强等优点的复合双网络型水凝胶,有望作为支架材料应用于更广泛的生物医学领域。
2、本发明利用原位聚合的方法,在壳聚糖和聚合(丙烯酰胺-马来酸酐)之间进行离子配位,先利用马来酸酐和丙烯酰胺发生自由基聚合生成长链,再利用P(MAH-r-AM)聚电解质链中丰富的-COOH基团与壳聚糖的-NH2偶联形成动态离子交联超分子网络;引入羧甲基化β-环糊精嵌入单宁酸的结构,再利用羧甲基化β-环糊精中羟基与壳聚糖中羟基和氨基通过静电吸附以及氢键作用连接在一起,形成双网络复合水凝胶;单宁酸中高含量的邻苯二酚和邻苯三酚使复合水凝胶具有类似贻贝的贴附性;由此,本发明制备的羧甲基β-环糊精负载单宁酸的壳聚糖/马来酸酐-丙烯酰胺双网络抗菌水凝胶具有优异的抗菌性,良好的生物相容性,贴附性强,在人造皮肤、韧带以及作为伤口绷带敷料等领域具有广阔的前景。
附图说明:
图1为本发明制备的水凝胶的扫描电镜图。
具体实施方式:
为了使本发明实现的技术手段、创作特征、达成目的与功效易于明白了解,下面结合具体实施例和图示,进一步阐述本发明。
空白对照
壳聚糖/丙烯酰胺-马来酸酐水凝胶的制备:室温下,将1g马来酸酐溶解于7.5g去离子水中,再加入0.2g壳聚糖,磁力搅拌12h,得到壳聚糖-马来酸酐溶液;于60℃恒温水浴锅中将2g丙烯酰胺加入到壳聚糖-马来酸酐溶液中,磁力搅拌反应2h后,降低温度至40℃加入0.6ml 56.8mmol/ml过硫酸铵作为引发剂、0.1ml 10mmol/ml N,N’-亚甲基双丙烯酰胺作为交联剂混合均匀,反应2h,即得水凝胶。
实施例1
(1)羧甲基化β-环糊精的干法制备:取6.0gβ-环糊精于研钵中研细,加入1.26gNaOH均匀混合后,滴入无水乙醇和水再均匀混合研磨,碱化1h后加入0.08g氯乙酸,研磨30min后放入40℃烘箱中30min,取出研磨30min,如此反复进行醚化反应4h,最后用乙醇洗涤3次,放入60℃烘箱中烘干。
(2)羧甲基化β-环糊精/单宁酸分散液的制备:室温下称取0.1g步骤(1)制备的羧甲基化β-环糊精粉末加入到1g去离子水中,机械搅拌1h后超声处理30min,并于机械搅拌30min时加入25mg单宁酸,制得羧甲基化β-环糊精/单宁酸分散液。
(3)水凝胶的制备:室温下将1g马来酸酐溶解于7.5g去离子水中,再加入0.2g壳聚糖,磁力搅拌12h,得到壳聚糖-马来酸酐溶液;于60℃恒温水浴锅中将2g丙烯酰胺、步骤(2)制备的羧甲基化β-环糊精/单宁酸分散液加入到壳聚糖-马来酸酐溶液中,磁力搅拌反应2h后,降低温度至40℃加入0.6ml 56.8mmol/ml过硫酸铵作为引发剂、0.1ml 10mmol/ml N,N’-亚甲基双丙烯酰胺作为交联剂混合均匀,反应2h,即得目标水凝胶。
实施例2
(1)羧甲基化β-环糊精的干法制备:取6.0gβ-环糊精于研钵中研细,加入1.26gNaOH均匀混合后,滴入无水乙醇和水再均匀混合研磨,碱化1h后加入0.08g氯乙酸,研磨30min后放入40℃烘箱中30min,取出研磨30min,如此反复进行醚化反应4h,最后用乙醇洗涤3次,放入60℃烘箱中烘干。
(2)羧甲基化β-环糊精/单宁酸分散液的制备:室温下称取0.1g步骤(1)制备的羧甲基化β-环糊精粉末加入到1g去离子水中,机械搅拌1h后超声处理30min,并于机械搅拌30min时加入50mg单宁酸,制得羧甲基化β-环糊精/单宁酸分散液。
(3)水凝胶的制备:室温下将1g马来酸酐溶解于7.5g去离子水中,再加入0.2g壳聚糖,磁力搅拌12h,得到壳聚糖-马来酸酐溶液;于60℃恒温水浴锅中将2g丙烯酰胺、步骤(2)制备的的羧甲基化β-环糊精/单宁酸分散液加入到壳聚糖-马来酸酐溶液中,磁力搅拌反应2h后,降低温度至40℃加入0.6ml56.8mmol/ml过硫酸铵作为引发剂、0.1ml 10mmol/ml N,N’-亚甲基双丙烯酰胺作为交联剂混合均匀,反应2h,即得目标水凝胶。
实施例3
(1)羧甲基化β-环糊精的干法制备:取6.0gβ-环糊精于研钵中研细,加入1.26gNaOH均匀混合后,滴入无水乙醇和水再均匀混合研磨,碱化1h后加入0.08g氯乙酸,研磨30min后放入40℃烘箱中30min,取出研磨30min,如此反复进行醚化反应4h,最后用乙醇洗涤3次,放入60℃烘箱中烘干。
(2)羧甲基化β-环糊精/单宁酸分散液的制备:室温下称取0.05g步骤(1)制备的羧甲基化β-环糊精粉末加入到1g去离子水中,机械搅拌1h后超声处理30min,并于机械搅拌30min时加入25mg单宁酸,制得羧甲基化β-环糊精/单宁酸分散液。
(3)水凝胶的制备:室温下将1g马来酸酐溶解于7.5g去离子水中,再加入0.2g壳聚糖,磁力搅拌12h,得到壳聚糖-马来酸酐溶液;于60℃恒温水浴锅中将2g丙烯酰胺、步骤(2)制备的羧甲基化β-环糊精/单宁酸分散液加入到壳聚糖-马来酸酐溶液中,磁力搅拌反应2h后,降低温度至40℃,依次加入0.6ml56.8mmol/ml过硫酸铵作为引发剂、0.1ml 10mmol/mlN,N’-亚甲基双丙烯酰胺作为交联剂混合均匀,反应2h,即得目标水凝胶。
对上述空白对照、实施例1、实施例2和实施例3制备的水凝胶进行抗菌试验,具体结果见表1。
表1抗菌水凝胶的抗菌率
抗菌试验表明,单宁酸作为一种多酚类物质,具有较强的清除自由基能力以及强抗氧化性。增加羧甲基β-环糊精负载的单宁酸含量,可以显著提升水凝胶的抗菌性。可见,利用本发明制备的抗菌水凝胶产品,抗菌性能较好。
通过红细胞的溶血实验来探究生物相容性,在红细胞溶血实验中,在红细胞中加入所测的样品,如果样品的生物相容性较差,就会使得红细胞破裂并释放出血红蛋白,通过测定其的释放量,可以计算出样品的溶血率,从而评价材料的生物相容性。以红细胞的溶血实验来评价改性氧化石墨烯负载纳米银/聚乙烯醇基抗菌水凝胶的生物相容性。
表2水凝胶的生物相容性
溶血率/% | |
实施例1 | 0.25 |
实施例2 | 0.38 |
实施例3 | 0.44 |
与阳性对照组(非离子型表面活性剂即0.1%TritonX-100处理过的红细胞)相比,羧甲基β-环糊精负载单宁酸的壳聚糖/马来酸酐-丙烯酰胺双网络抗菌水凝胶溶血率均低于10%,说明羧甲基β-环糊精负载单宁酸的壳聚糖/马来酸酐-丙烯酰胺双网络抗菌水凝胶具有良好的生物相容性。
综上表明,本发明提供了一种利用壳聚糖水溶液中马来酸酐和丙烯酰胺单体的原位聚合,在壳聚糖和聚合(丙烯酰胺-马来酸酐)之间进行离子配位,制备了一类新型的超分子纳米纤维结构杂化水凝胶。通过羧甲基化改性β-环糊精,加入单宁酸,增强其与客体单宁酸形成包容物的水溶性,进一步提高了对细菌的抗菌活性以及体外抗氧化能力,制备出具有结构适应性强、孔隙率高、粘附性能优异,抗氧化能力强和抗菌活性强等优点的复合双网络型水凝胶,有望作为支架材料应用于更广泛的生物医学领域。
以上显示和描述了本发明的基本原理和主要特征和本发明的优点。本行业的技术人员应该了解,本发明不受上述实施例的限制,上述实施例和说明书中描述的只是说明本发明的原理,在不脱离本发明精神和范围的前提下,本发明还会有各种变化和改进,这些变化和改进都落入要求保护的本发明范围内。本发明要求保护范围由所附的权利要求书及其等效物界定。
Claims (8)
1.一种CM-β-CD负载鞣酸聚丙烯酰胺型双网络抗菌水凝胶,其特征在于:按重量组分计,包括80-100份丙烯酰胺、40-50份马来酸酐、16-20份壳聚糖、4-8份羧甲基化β-环糊精和2-4份单宁酸;
其制备方法包括如下步骤:
(1) 羧甲基化β-环糊精的干法制备:取β-环糊精研细,加碱研磨,再滴入无水乙醇和水研磨,碱化后加入氯乙酸,研磨一段时间后放入烘箱中,取出后继续研磨,如此反复进行醚化反应,最后用乙醇洗涤,烘干;
(2) 羧甲基化β-环糊精/单宁酸分散液的制备:将步骤(1)制备的羧甲基化β-环糊精粉末加入到去离子水中,搅拌后超声处理,并加入单宁酸,制得羧甲基化β-环糊精/单宁酸分散液;
(3) 水凝胶的制备:将马来酸酐溶解于去离子水中,再加入壳聚糖混合,得到壳聚糖-马来酸酐溶液;然后将丙烯酰胺、步骤(2)制备的羧甲基化β-环糊精/单宁酸分散液加入到壳聚糖-马来酸酐溶液中,反应一段时间后,降温加入引发剂、交联剂进行反应,得到CM-β-CD负载鞣酸聚丙烯酰胺型双网络抗菌水凝胶。
2.根据权利要求1所述的CM-β-CD负载鞣酸聚丙烯酰胺型双网络抗菌水凝胶,其特征在于:所述步骤(1)中碱为NaOH。
3.根据权利要求1所述的CM-β-CD负载鞣酸聚丙烯酰胺型双网络抗菌水凝胶,其特征在于:所述步骤(1)中碱化时间为0.5-1.5h。
4.根据权利要求1所述的CM-β-CD负载鞣酸聚丙烯酰胺型双网络抗菌水凝胶,其特征在于:所述步骤(1)中碱与β-环糊精的重量比为(0.2-0.25) : 1。
5.根据权利要求1所述的CM-β-CD负载鞣酸聚丙烯酰胺型双网络抗菌水凝胶,其特征在于:所述步骤(1)中醚化反应时的烘箱温度为40℃-50℃。
6.根据权利要求1所述的CM-β-CD负载鞣酸聚丙烯酰胺型双网络抗菌水凝胶,其特征在于:所述步骤(3)中反应温度为50-60℃,反应时间为2-3h,降低温度至30-40℃。
7.根据权利要求1所述的CM-β-CD负载鞣酸聚丙烯酰胺型双网络抗菌水凝胶,其特征在于:所述步骤(3)中引发剂为过硫酸钾。
8.根据权利要求1所述的CM-β-CD负载鞣酸聚丙烯酰胺型双网络抗菌水凝胶,其特征在于:所述步骤(3)中交联剂为N,N’-亚甲基双丙烯酰胺。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111630532.XA CN114404646B (zh) | 2021-12-28 | 2021-12-28 | CM-β-CD负载鞣酸聚丙烯酰胺型双网络抗菌水凝胶 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111630532.XA CN114404646B (zh) | 2021-12-28 | 2021-12-28 | CM-β-CD负载鞣酸聚丙烯酰胺型双网络抗菌水凝胶 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114404646A CN114404646A (zh) | 2022-04-29 |
CN114404646B true CN114404646B (zh) | 2022-10-11 |
Family
ID=81269097
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111630532.XA Active CN114404646B (zh) | 2021-12-28 | 2021-12-28 | CM-β-CD负载鞣酸聚丙烯酰胺型双网络抗菌水凝胶 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114404646B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114940493B (zh) * | 2022-06-08 | 2024-04-19 | 合肥艾克思维新材料科技有限公司 | 石墨烯的剥离方法、石墨烯柔性膜及其制备方法 |
CN115887738B (zh) * | 2022-12-16 | 2024-05-10 | 湖南师范大学 | 一种聚丙烯酰胺-壳聚糖/高岭土多孔材料及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002017979A2 (en) * | 2000-08-29 | 2002-03-07 | Noveon Ip Holdings Corp. | Dehydrated hydrogels |
WO2010111238A2 (en) * | 2009-03-23 | 2010-09-30 | Micell Technologies, Inc. | Improved biodegradable polymers |
WO2016007692A1 (en) * | 2014-07-09 | 2016-01-14 | Lubrizol Advanced Materials, Inc. | Hydrogel compositions |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010007673A1 (en) * | 1999-11-12 | 2001-07-12 | Merrill Seymour Goldenberg | Sustained-release delayed gels |
CN110090317B (zh) * | 2019-04-26 | 2020-07-03 | 非零和(北京)投资管理有限公司 | 一种超吸水性高分子水凝胶抗菌海绵及其制备方法和用途 |
US20220409746A1 (en) * | 2019-07-15 | 2022-12-29 | Duke University | Nucleic acid loaded flowable hydrogels and compositions, systems and methods related thereto |
CN111012683B (zh) * | 2019-11-12 | 2022-05-17 | 北京工商大学 | 一种以纳米银作为着色成分的染发剂及制备方法 |
CN113754830A (zh) * | 2021-08-09 | 2021-12-07 | 华南理工大学 | 一种具有湿态粘附性能的水凝胶及其制备方法和应用 |
CN113637183A (zh) * | 2021-08-17 | 2021-11-12 | 安徽大学 | 改性石墨烯负载纳米银/聚乙烯醇抗菌水凝胶及其制备方法 |
-
2021
- 2021-12-28 CN CN202111630532.XA patent/CN114404646B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002017979A2 (en) * | 2000-08-29 | 2002-03-07 | Noveon Ip Holdings Corp. | Dehydrated hydrogels |
WO2010111238A2 (en) * | 2009-03-23 | 2010-09-30 | Micell Technologies, Inc. | Improved biodegradable polymers |
WO2016007692A1 (en) * | 2014-07-09 | 2016-01-14 | Lubrizol Advanced Materials, Inc. | Hydrogel compositions |
Non-Patent Citations (4)
Title |
---|
Cu~(2+)吸附用Fe_3O_4/淀粉接枝聚丙烯酸磁性微球的制备;杨小玲等;《中国胶粘剂》;20121130(第11期);第10-14页 * |
Evaluating the performance of bridging-assembly chelating flocculant for heavy metals removal: Role of branched architectures;Wei Chen等;《Chemosphere》;20211212;第289卷;第1-12页 * |
β-cyclodextrin chitosan-based hydrogels with tunable pH-responsive properties for controlled release of acyclovir: design, characterization, safety, and pharmacokinetic evaluation;Nadia Shamshad Malik等;《DRUG DELIVERY》;20210611;第28卷(第1期);第1093-1108页 * |
壳聚糖及其衍生物固载环糊精的制备及应用研究进展;程德书等;《化工进展》;20080605(第06期);第819-824+830页 * |
Also Published As
Publication number | Publication date |
---|---|
CN114404646A (zh) | 2022-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Amirian et al. | In-situ crosslinked hydrogel based on amidated pectin/oxidized chitosan as potential wound dressing for skin repairing | |
Li et al. | Injectable, self-healing, antibacterial, and hemostatic N, O-carboxymethyl chitosan/oxidized chondroitin sulfate composite hydrogel for wound dressing | |
Li et al. | Fabrication of PVA/PAAm IPN hydrogel with high adhesion and enhanced mechanical properties for body sensors and antibacterial activity | |
CN114404646B (zh) | CM-β-CD负载鞣酸聚丙烯酰胺型双网络抗菌水凝胶 | |
Tsao et al. | Evaluation of chitosan/γ-poly (glutamic acid) polyelectrolyte complex for wound dressing materials | |
CN111154149A (zh) | 一种水凝胶及其制备方法与敷料 | |
CN113004543B (zh) | 一种纳米木质素/聚乙烯醇复合医用水凝胶及其制备方法 | |
CN109369948B (zh) | 一种细菌纤维素/聚乙烯醇抗菌水凝胶及其制备方法和应用 | |
CN103446621A (zh) | 一种含纳米银的海藻酸钠基抗菌医用敷料及其制备方法 | |
CN113637183A (zh) | 改性石墨烯负载纳米银/聚乙烯醇抗菌水凝胶及其制备方法 | |
CN107141519B (zh) | 一种改性壳聚糖基超吸水凝胶及其制备和应用 | |
CN113185714B (zh) | 一种高粘附性抗菌促愈合水凝胶及其制备方法 | |
CN113244442B (zh) | 多氨基阳离子化合物在制备表面促凝血增强型止血材料上的应用 | |
CN110665051A (zh) | 一种具有止血和抗菌性的冷冻凝胶支架的制备方法 | |
CN107088236A (zh) | 一种增强型抗菌止血生物海绵的制备方法 | |
CN112402688A (zh) | 一种生物相容性且抗菌的快速止血纳米材料及其制备方法 | |
CN114522270B (zh) | 止血粉的制备方法 | |
Jiang et al. | Hydrophobically modified hydrogel with enhanced tissue adhesion and antibacterial capacity for wound healing | |
Haima et al. | Synthesis and characterisation of glutaraldehyde cross-linked κ-carrageenan-gelatin hydrogel | |
CN112451730A (zh) | 一种快速促进皮肤伤口愈合的水凝胶纱布的制备方法 | |
CN115850733B (zh) | 一种可注射用纳米粘土水凝胶及其制备方法和应用 | |
CN114159627B (zh) | 一种用于监测和治疗尿路感染的复合水凝胶涂层及其制备方法与应用 | |
TWI499436B (zh) | 纖維水凝膠及其製備方法 | |
CN114832153A (zh) | 多糖类织物增强基抗菌止血多功能水凝胶敷料 | |
CN118059299B (zh) | 生物多糖修饰的壳聚糖抗菌生物材料及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |